Home
|
Inbox
|
Search
|
View Abstract
Use of Mepolizumab in the Treatment of Severe Eosinophilic Asthma
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A1405 - Use of Mepolizumab in the Treatment of Severe Eosinophilic Asthma
Author Block: R. A. Strauss; Cleveland Allergy and Asthma Center, Fairview Park, OH, United States.
INTRODUCTION:
Mepolizumab, a monoclonal antibody directed against interleukin 5 cytokine, which is involved in the eosinophil lifecycle, has been shown in several large controlled studies to decrease symptoms in asthmatics with an eosinophilic phenotype.
RATIONALE:
Double blind controlled studies have shown the efficacy of mepolizumab. I would like to report the real-world use and the results of using this drug in clinical practice.
METHODS:
This was a retrospective study in the use of mepolizumab in 36 asthmatic patients with an eosinophil count of at least 150 cells/mcL. They had chronic asthma requiring daily high dose inhaled corticosteroids with a long-acting beta agonist (ICS/LABA), as well as additional controller medication. The series included 13 steroid-dependent asthmatics requiring 7 to 25 mg of prednisone per day. Those not on daily prednisone required at least two bursts of prednisone and frequent use of an MDI or nebulizer with albuterol. Each patient served as their own control, comparing the number of exacerbations during the time period before mepolizumab to the number of exacerbations while on mepolizumab. The patients received an injection of mepolizumab one time per month, pulmonary function tests were performed, the patient was examined and filled out an asthma control questionnaire (ACQ).
RESULTS:
During a period of 6 to 14 months before treatment with mepolizumab, there were 121 exacerbations. After receiving monthly mepolizumab injections, there were 25 exacerbations; an average of 3.2 bursts of prednisone before mepolizumab and 0.7 after mepolizumab, an 80% reduction. 19 out of 36 patients did not require a burst of prednisone while on mepolizumab. In the 13 steroid-dependent asthmatics who required 7 to 25 mg of prednisone per day, 7 were able to discontinue prednisone altogether after an average of six months, with a range of 1 to 12 months. 6 patients still required prednisone from 10 mg per day to 5 mg every other day.
In the 36 patients, the ACQ before mepolizumab ranged from 0.28 to 4.0, with an average of 1.69; after receiving mepolizumab, the ACQ score ranged from 0 to 3.42, with an average of 0.93, a 55% reduction.
CONCLUSION:
Mepolizumab should be offered to asthmatic who are steroid-dependent or requires high dose ICS with LABA and additional controller medications, who have had at least two bursts of prednisone and frequent use of a rescue inhaler. Significant decrease in symptoms and oral corticosteroid requirements should be expected.
Author Block: R. A. Strauss; Cleveland Allergy and Asthma Center, Fairview Park, OH, United States.
INTRODUCTION:
Mepolizumab, a monoclonal antibody directed against interleukin 5 cytokine, which is involved in the eosinophil lifecycle, has been shown in several large controlled studies to decrease symptoms in asthmatics with an eosinophilic phenotype.
RATIONALE:
Double blind controlled studies have shown the efficacy of mepolizumab. I would like to report the real-world use and the results of using this drug in clinical practice.
METHODS:
This was a retrospective study in the use of mepolizumab in 36 asthmatic patients with an eosinophil count of at least 150 cells/mcL. They had chronic asthma requiring daily high dose inhaled corticosteroids with a long-acting beta agonist (ICS/LABA), as well as additional controller medication. The series included 13 steroid-dependent asthmatics requiring 7 to 25 mg of prednisone per day. Those not on daily prednisone required at least two bursts of prednisone and frequent use of an MDI or nebulizer with albuterol. Each patient served as their own control, comparing the number of exacerbations during the time period before mepolizumab to the number of exacerbations while on mepolizumab. The patients received an injection of mepolizumab one time per month, pulmonary function tests were performed, the patient was examined and filled out an asthma control questionnaire (ACQ).
RESULTS:
During a period of 6 to 14 months before treatment with mepolizumab, there were 121 exacerbations. After receiving monthly mepolizumab injections, there were 25 exacerbations; an average of 3.2 bursts of prednisone before mepolizumab and 0.7 after mepolizumab, an 80% reduction. 19 out of 36 patients did not require a burst of prednisone while on mepolizumab. In the 13 steroid-dependent asthmatics who required 7 to 25 mg of prednisone per day, 7 were able to discontinue prednisone altogether after an average of six months, with a range of 1 to 12 months. 6 patients still required prednisone from 10 mg per day to 5 mg every other day.
In the 36 patients, the ACQ before mepolizumab ranged from 0.28 to 4.0, with an average of 1.69; after receiving mepolizumab, the ACQ score ranged from 0 to 3.42, with an average of 0.93, a 55% reduction.
CONCLUSION:
Mepolizumab should be offered to asthmatic who are steroid-dependent or requires high dose ICS with LABA and additional controller medications, who have had at least two bursts of prednisone and frequent use of a rescue inhaler. Significant decrease in symptoms and oral corticosteroid requirements should be expected.
|
Home
|
Inbox
|
Search
|